drugset / Trial / NCT00516165
RAD001 in Advanced Hepatocellular Carcinoma
Phase 1/2
Completed
28 enrolled
Massachusetts General Hospital
Beth Israel Deaconess Medical Center · collabDana-Farber Cancer Institute · collabNovartis · collab
NaSingle-groupOpen-labelTreatment
Summary
Laboratory studies have shown that RAD001 can prevent cells from multiplying. Consequently, the study drug is being tested in medical conditions in which excessive cell multiplication (as in cancer) needs to be stopped. The main purpose of this research study is to find the highest dose of RAD001 that can be given safely (without causing severe side effects) and to learn the effects (good or bad) RAD001 has on participants with liver cancer.
Timeline
- Start
- 2007-08
- Primary completion
- 2010-01
- Completion
- 2011-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |